Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at A
ABP-671 effective at lowering serum uric acid, the cause of gout JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today that it will present final dated data from its Phase 2a clinical trial of its s...
Source: pharmiweb.com